Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

Carolyn D. Britten • Alex A. Adjei • Robert Millham •
Brett E. Houk • Gary Borzillo • Kristen Pierce •
Zev A. Wainberg • Patricia M. LoRusso

Published online: 9 February 2014
© Springer Science+Business Media New York 2014

Erratum to: Invest New Drugs
DOI 10.1007/s10637-013-0062-5

In the original version of this article, the following was omitted:

Acknowledgments The study was sponsored by Pfizer Inc.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-013-0062-5>.

C. D. Britten • Z. A. Wainberg
UCLA Medical Center, Los Angeles, CA, USA

A. A. Adjei
Roswell Park Cancer Institute, Buffalo, NY, USA

R. Millham • G. Borzillo • K. Pierce
Pfizer Oncology, Groton, CT, USA

B. E. Houk
Pfizer Oncology, La Jolla, CA, USA

P. M. LoRusso
Karmanos Cancer Institute, Detroit, MI, USA

Present Address:

C. D. Britten (✉)
Division of Hematology/Oncology, Medical University of South
Carolina, 173 Ashley Avenue, MSC 635 BSB 102, Charleston,
SC 29425, USA
e-mail: britten@musc.edu